Celgene Corporation announced the appointment of Dr. Alise Reicin to President, Global Clinical Development, reporting to Mark J. Alles, Chairman and Chief Executive Officer, effective November 1, 2018. In this role, Dr. Reicin will be responsible for all aspects of mid- to late-stage clinical development across Celgene’s portfolio and will serve on the company's Executive Committee. The appointment of Dr. Reicin is part of a deliberate strategy to strengthen Celgene for long-term success. This organizational change further establishes clinical development as another center of excellence and enhances strategic leadership in discovery, development and commercialization. Dr. Rupert Vessey continues to lead early research and development. Dr. Reicin will lead mid- to late-stage clinical development, clinical operations, biostatistics, project leadership and project management. Dr. Jay Backstrom maintains responsibility for the company's global regulatory strategy, drug safety, regulatory operations and pharmacovigilance. Nadim Ahmed and Terrie Curran continue to lead the company's global commercial and medical affairs organizations for the Hematology & Oncology and Inflammation & Immunology franchises, respectively. Dr. Reicin was most recently Senior Vice President and Head of Global Clinical Development in Research and Development (R&D) at EMD Serono. In this role, she has been responsible for the clinical development of assets across oncology and inflammatory indications, including anti-PD-L1 avelumab in solid tumors and cladribine in relapsing multiple sclerosis. Since joining EMD Serono in 2015, she has led clinical development, biostatistics, clinical operations, and the Japan and China R&D hubs. Prior to joining EMD Serono, Dr. Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck, Sharp & Dohme (Merck).